Elicio Therapeutics
ELTX
15 hedge funds and large institutions have $2.71M invested in Elicio Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 16 closing their positions.
6% more capital invested
Capital invested by funds: $2.56M → $2.71M (+$150K)
11.45% less ownership
Funds ownership: 14.86% → 3.41% (-11%)
46% less funds holding
Funds holding: 28 → 15 (-13)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHC
Meyer Handelman Company
Rye Brook,
New York
|
+$121K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$68.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.2K |
| 4 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$3.21K |
| 5 |
NCM
Northwest Capital Management
Lake Oswego,
Oregon
|
+$3.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$621K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
-$138K |
| 3 |
Renaissance Technologies
New York
|
-$54K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$45.9K |
| 5 |
Millennium Management
New York
|
-$40K |
ELTX Hedge Fund Activity: Q2 2023 in Review
15 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q2 2023, worth a combined $2.71M — up 5.9% from $2.56M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ELTX and 3 opened new positions — a net loss of 13 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Meyer Handelman Company, opening a new position worth an estimated $121K. The largest seller was BVF Inc, exiting entirely with an estimated $621K sold.
- 15 institutional investors held Elicio Therapeutics (ELTX) as of Q2 2023, down from 28 in Q1 2023.
- Funds reported $2.71M of Elicio Therapeutics stock for Q2 2023, up 5.9% quarter-over-quarter.
- 3 funds opened new Elicio Therapeutics positions in Q2 2023 and 16 closed out, a net change of -13 holders.
- The largest Elicio Therapeutics buyer in Q2 2023 was Meyer Handelman Company, an estimated $121K added.
- The largest Elicio Therapeutics seller in Q2 2023 was BVF Inc, an estimated $621K sold.
Based on aggregated 13F filings for Q2 2023.